Ingavirin
Ingavirin: instructions for use and reviews
- 1. Release form and composition
- 2. Pharmacological properties
- 3. Indications for use
- 4. Contraindications
- 5. Method of application and dosage
- 6. Side effects
- 7. Overdose
- 8. Special instructions
- 9. Application during pregnancy and lactation
- 10. Use in childhood
- 11. Drug interactions
- 12. Analogs
- 13. Terms and conditions of storage
- 14. Terms of dispensing from pharmacies
- 15. Reviews
- 16. Price in pharmacies
Latin name: Ingavirin
ATX code: J05AX
Active ingredient: Imidazolylethanamide of pentanedioic acid
Producer: OJSC "Valenta Pharmaceuticals", Russia
Description and photo update: 18.10.2018
Prices in pharmacies: from 300 rubles.
Buy
Ingavirin is an innovative antiviral drug with a unique mechanism of action and a wide range of antiviral activity, its use within two days from the onset of the disease reduces the period of intoxication, fever and catarrhal symptoms, reducing viral load and significantly reducing the risk of complications.
Release form and composition
The drug is produced in the form of capsules of size No. 2, with a white logo on the cap of the capsule in the form of the letter "I" inside the ring, filled with granules and powder of almost white or white color; clumping of the filler is allowed, which is eliminated with weak mechanical stress:
- dosage of 30 mg: blue (7 pcs. in blisters, in a pack of 1 or 2 packs);
- dosage 60 mg: yellow (7 pcs. in blisters, 1 pack in a pack);
- dosage 90 mg: red (7 pcs. in blisters, 1 pack in a pack).
Composition for 1 capsule:
- active substance: vitaglutam (imidazolylethanamide of pentanedioic acid) - 30, 60 or 90 mg;
- auxiliary ingredients: lactose monohydrate, potato starch, colloidal silicon dioxide (aerosil), magnesium stearate;
- logo ink: shellac, titanium dioxide, propylene glycol.
Shell composition:
- capsules 30 mg: gelatin, titanium dioxide, dyes (brilliant black, blue patented, crimson - Ponso 4R, azorubin);
- 60 mg capsules: gelatin, titanium dioxide, iron dye yellow oxide;
- 90 mg capsules: gelatin, titanium dioxide, dyes (azorubin, crimson - Ponso 4R and quinoline yellow).
Pharmacological properties
Pharmacodynamics
Antiviral drug with proven efficacy in preclinical and clinical studies against influenza A - A (H1N1) viruses, including swine influenza A (H1N1) pdm09, A (H5N1), A (M3N2) and type B, virus parainfluenza, adenovirus, RSV (respiratory syncytial virus). According to the results of preclinical studies, the drug is also effective against metapneumovirus, coronavirus and enteroviruses, including rhinovirus and Coxsackie virus.
Ingavirin accelerates the elimination of viruses, which helps to shorten the duration of the disease and reduce the likelihood of complications. The mechanism of action of vitaglutam is realized at the level of infected cells by stimulating factors of innate immunity, inhibited by viral proteins. In the course of the experiments, it was established, in particular, that imidazolylethanamide of pentanedioic acid increases the expression of the IFNAR type I interferon receptor on the surface of epithelial immunocompetent cells. With an increase in the density of interferon receptors, the sensitivity of cells to endogenous interferon signals increases. The process occurs with phosphorylation (activation) of the STAT1 transmitter protein, which transmits a signal to the cell nucleus, inducing the activity of antiviral genes. In the presence of infection, the production of antiviral effector protein M × A is stimulated,suppressing the intracellular transport of ribonucleoproteins of different viruses, which slows down viral replication.
Vitaglutam increases the level of interferon in the blood to the physiological norm, stimulating and normalizing the reduced α- and γ-interferon-producing ability of blood leukocytes. It activates the generation of cytotoxic lymphocytes, increases the content of NK-T cells, which have high killer activity in relation to cells infected with viruses.
The anti-inflammatory effect is provided by inhibition of the production of key pro-inflammatory cytokines [tumor necrosis factor (TNF-α), interleukins (IL-1β and IL-6)] and a decrease in myeloperoxidase activity. It has been experimentally proven that the use of Ingavirin in conjunction with antibiotics enhances the effectiveness of therapy on the model of bacterial sepsis, including that caused by penicillin-resistant staphylococcus strains. An experimental study of the toxicological effect of pentanedioic acid imidazolylethanamide showed a low level of toxicity and a high safety profile of the drug. According to the parameters of acute toxicity, Ingavirin belongs to the IV class - "Low toxic substances" (lethal doses of the drug in determining the LD50 during experiments on acute toxicity could not be established).
Pharmacokinetics
When taking vitaglutam in recommended doses, it is not possible to determine its content in blood plasma by available methods.
In experimental studies with the use of a radioactive label, it was established that vitaglutam enters the bloodstream from the gastrointestinal tract quickly and is evenly distributed throughout the internal organs. The maximum concentration reaches in the blood and most organs half an hour after administration. The values of the area under the pharmacokinetic curve "concentration-time" (AUC) of the liver, kidneys and lungs slightly exceed the AUC of blood equal to 43.77 μg · h / g, and the AUC of the adrenal glands, spleen, thymus and lymph nodes is below the AUC of blood. The median retention time (MRT) in the blood is 37.2 hours.
With a 5-day course of taking capsules orally once a day, imidazolylethanamide of pentanedioic acid accumulates in tissues and internal organs. The qualitative parameters of the pharmacokinetic curves after each administration were identical: a rapid increase in the concentration of the drug immediately after administration with a further slow decrease by 24 hours.
Vitaglutam is not metabolized in the body, 77% is excreted unchanged through the intestines and 23% - by the kidneys. Within 24 hours, up to 80% of the received dose is excreted: 34.8% - within 0 to 5 hours after administration and 45.2% - from 5 to 24 hours.
Indications for use
- Ingavirin 30 mg: therapy of influenza viruses of type A and B, other acute respiratory viral infections (acute respiratory viral infections), including parainfluenza, adenovirus infection, respiratory syncytial infection in adults and children over 13 years old; prevention of influenza viruses type A and B, as well as other acute respiratory viral infections in adult patients;
- Ingavirin 60 mg: therapy of influenza viruses of type A and B, other acute respiratory viral infections, including parainfluenza, adenovirus infection, respiratory syncytial infection in children 7–17 years old;
- Ingavirin 90 mg: therapy for influenza A and B viruses, other ARVI (acute respiratory viral infections), including parainfluenza, adenovirus infection, respiratory syncytial infection in adults; prevention of influenza viruses type A and B, as well as other acute respiratory viral infections in adult patients.
Contraindications
Absolute contraindications common to all forms of release:
- the period of pregnancy and lactation (breastfeeding);
- lactose intolerance, lactase deficiency, glucose-galactose malabsorption;
- increased individual sensitivity to drug components.
Capsules in a dosage of 30 and 90 mg are contraindicated for children under 13 years of age when treating influenza A and B viruses and other acute respiratory viral infections, for children and adolescents under 18 years of age for the prevention of these diseases.
Capsules at a dosage of 60 mg are contraindicated for children under 7 years of age and persons over 18 years of age (due to the impossibility of the drug in this dosage form to provide vitaglutam at a dose of 90 mg).
Instructions for the use of Ingavirin: method and dosage
Ingavirin is taken orally, the effectiveness of the drug does not depend on food intake. It is necessary to start treatment from the moment the first signs appear, but no later than 2 days from the onset of the disease.
Recommended dosage provided that the drug is taken once a day:
- capsules at a dosage of 30 and 90 mg: therapy of influenza and ARVI in adult patients - 90 mg each (1 pc. 90 mg or 3 pcs. 30 mg each), in children 13-17 years old - 60 mg (2 pcs. 30 mg); prevention of influenza and ARVI after contact with infected persons for adults - 90 mg each (1 piece 90 mg each or 3 pieces 30 mg each);
- capsules in a dosage of 60 mg: therapy of influenza and ARVI in children 7–17 years old - 60 mg (1 pc. 60 mg).
The duration of treatment is 5-7 days, depending on the severity of the condition, the duration of prophylactic administration is 7 days.
Side effects
Taking Ingavirin can, in rare cases, cause hypersensitivity reactions.
Overdose
To date, no cases of Ingavirin overdose have been reported.
special instructions
It is not recommended to take Ingavirin at the same time as other antiviral drugs.
Influence on the ability to drive vehicles and complex mechanisms
The effect of the drug on the speed of psychomotor reactions and concentration of attention has not been studied. But, given the mechanism of its effect on the body and the profile of side effects, it can be assumed that it does not affect the ability to perform work of increased complexity, including driving.
Application during pregnancy and lactation
Due to the lack of data on the efficacy and safety of using Ingavirin by pregnant and lactating women, its use is contraindicated during these periods. In case of vital necessity to use the drug during lactation, breastfeeding should be interrupted.
Pediatric use
According to the instructions, Ingavirin is used in children according to indications.
Drug interactions
There is no data on the drug interaction of pentanedioic acid imidazolylethanamide with other substances / drugs.
Analogs
Ingavirin analogs are: Lavomax, Arbidol, Amizon, Amiksin, Kagocel, Vitaglutam, Dicarbamine, etc.
Terms and conditions of storage
Store in a place protected from direct sunlight at a temperature not exceeding 25 ° C. Keep out of the reach of children.
Shelf life: Ingavirin 60 mg - 3 years; Ingavirin 90 and 30 mg - 2 years.
Terms of dispensing from pharmacies
Available without a prescription.
Reviews about Ingavirin
Reviews about Ingavirin are common and differ in a wide variety of opinions. The average assessment of the drug on medical forums on a 5-point scale is 3.86 points. Some patients talk about the effectiveness and fast action of the drug, but you can also often find negative reviews, claiming that taking the drug does not alleviate the condition, but increases the manifestation of the symptoms of the disease.
Experts testify that if Ingavirin is used in compliance with the recommendations, it helps to quickly eliminate the symptoms of the disease and helps the body fight the virus more effectively.
The price of Ingavirin in pharmacies
Ingavirin price:
- capsules 60 mg (for children) 7 pcs. in the package - from 350 rubles;
- capsules 90 mg, 7 pcs. in the package - from 410 rubles.
Ingavirin: prices in online pharmacies
|
Drug name Price Pharmacy |
|
Ingavirin 60 mg capsules 7 pcs. RUB 300 Buy |
|
Ingavirin 90 mg capsules 7 pcs. 459 r Buy |
|
Ingavirin 60 mg capsules 10 pcs. 468 r Buy |
|
Ingavirin 60mg capsules for children 10 pcs. RUB 536 Buy |
|
Ingavirin 90 mg capsules 10 pcs. 577 r Buy |
|
Ingavirin capsules 90mg 10 pcs. 596 r Buy |
Maria Kulkes Medical journalist About the author
Education: First Moscow State Medical University named after I. M. Sechenov, specialty "General Medicine".
Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!
